ibi110
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04085185)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Esophageal Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 1
- Immune Checkpoint Inhibitors · Phase 2
- Lymphoma · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Melanoma · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06494943 | Phase 1 | Jun 26, 2024 | Fudan University |
| NCT06078657 | Phase 2 | Oct 31, 2023 | Zhengzhou University |
| NCT05572463 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05088967 | Phase 1 | Oct 20, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05039658 | Phase 1 | Sep 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05026593 | Phase 2 | Sep 7, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04085185 | Phase 1 | Sep 30, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 5 | 5 | 2 | 2019 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhengzhou University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1